TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00961298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: All subjects will receive single-blind placebo for the first two weeks, and then duloxetine for the next 12 weeks, followed by an up to 2 week taper off of the duloxetine. After 2 weeks of placebo daily, subjects will receive 30 mg per day of duloxetine for two weeks, then titrated up to 60 mg per day of duloxetine at week 2. A dosage decrease to 30 mg daily is permittable after week 2. This will be a flexible dose study with doses of duloxetine progressively increasing at weeks 4 (90 mg daily) and 6 (120 mg daily) in conjunction with CGI-I scores, to reach 120 mg daily or the maximum tolerated dose, if less than 120 mg daily at Week 12. There will be a post-taper follow up appointment at Week 14. Of Note: Amendment IRB Approved 6/14/11 Study Ending at Week 12 with removal of Week 14 visit as part of study.
Study: NCT00153543

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7 + PPV23, 2 months
Study: NCT04044352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/Bethesda/MM2/H1N1 Challenge
Description: Reverse-genetics derived live A/California/04/2009/H1N1-like influenza virus passaged six times in Vero cells.
Study: NCT00153543

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV7 + PPV23, 2 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7 + PPV23, 6 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV7 + PPV23, 6 months
Study: NCT04223752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam
Description: Participants 12 to \<18 years of age: IV ceftolozane 2 g with tazobactam 1 g infused over a 60-minute period.~Participants \<12 years of age: IV ceftolozane 40 mg/kg with tazobactam 20 mg/kg infused over a 60-minute period (not to exceed a dose of ceftolozane 2g and tazobactam 1 g).
Study: NCT04586270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS0612
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS0612
Description: oral tablets
Study: NCT02955030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NSV0001
Description: sublingual

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NSV0001
Description: sublingual

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NSV0001
Description: sublingual

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza HA vaccine Biken HA
Description: subcutaneous
Study: NCT04176926

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: Diagnostic Test: Simultaneous assessment of heart rhythm by 12-lead ECG and wearable device characterization of heart rhythm.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: Diagnostic Test: Simultaneous assessment of heart rhythm by 12-lead ECG and wearable device characterization of heart rhythm.
Study: NCT02534129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difinsa53
Description: Difinsa53 cream is applied to one half of radiation field

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aquaphor
Description: Aquaphor is applied to one half of radiation field
Study: NCT00826371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5 mg
Study: NCT02955030

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sublingual
Study: NCT03928028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Treatment
Description: Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Treatment
Description: Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Treatment
Description: Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
Study: NCT04379193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroproprioceptive facilitation and inhibition physical therapy
Description: All groups underwent two months' therapy, 16 face-to-face sessions (1 hour, twice a week for two months).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroproprioceptive facilitation and inhibition physical therapy
Description: All groups underwent two months' therapy, 16 face-to-face sessions (1 hour, twice a week for two months).
Study: NCT02594748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management education
Description: The intervention group will receive diabetes self-management education based on the idea of extended theory of planned behavior .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: They will attend the routine lecture in hospital sit and listen, usually 1-2 times during one week in hospital
Study: NCT04158414

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR scan
Description: 500 cancer patients referred to PET-CT assessment will undergo PET/MR scan as well, and the net data will be compared. The overall data will be investigated in groups and subgroups of patients that share similar clinical characteristics and represent cancer patients in different time points during the natural history of their disease. Data analysis will be performed both visually and quantitatively using different MR and PET parameters according to the patient group. Specific populations will be detailed in the next sections per malignancy.
Study: NCT04223752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam
Description: Participants 12 to \<18 years of age: IV ceftolozane 2 g with tazobactam 1 g infused over a 60-minute period.~Participants \<12 years of age: IV ceftolozane 40 mg/kg with tazobactam 20 mg/kg infused over a 60-minute period (not to exceed a dose of ceftolozane 2g and tazobactam 1 g).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam
Description: Participants 12 to \<18 years of age: IV ceftolozane 2 g with tazobactam 1 g infused over a 60-minute period.~Participants \<12 years of age: IV ceftolozane 40 mg/kg with tazobactam 20 mg/kg infused over a 60-minute period (not to exceed a dose of ceftolozane 2g and tazobactam 1 g).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam
Description: Participants 12 to \<18 years of age: IV ceftolozane 2 g with tazobactam 1 g infused over a 60-minute period.~Participants \<12 years of age: IV ceftolozane 40 mg/kg with tazobactam 20 mg/kg infused over a 60-minute period (not to exceed a dose of ceftolozane 2g and tazobactam 1 g).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam
Description: Participants 12 to \<18 years of age: IV ceftolozane 2 g with tazobactam 1 g infused over a 60-minute period.~Participants \<12 years of age: IV ceftolozane 40 mg/kg with tazobactam 20 mg/kg infused over a 60-minute period (not to exceed a dose of ceftolozane 2g and tazobactam 1 g).
Study: NCT03169881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin
Description: Darbepoetin 10 micrograms/kg/once every week (IV or SC). Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline for IV administration, or sham dosing. Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
Study: NCT04255810

Intervention type: PROCEDURE
Intervention: Surgical collection of biospecimens
Description: Systemic blood and implant capsule tissue will be collected from two cohorts with breast implants, systemic blood only will be collected from Mastopexy cohort

Intervention type: PROCEDURE
Intervention: Surgical collection of biospecimens
Description: Systemic blood and implant capsule tissue will be collected from two cohorts with breast implants, systemic blood only will be collected from Mastopexy cohort
Study: NCT01670448

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PECBLOCK under echoguidance
Description: Performance of block under echography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECBLOCK under echoguidance
Description: Performance of block under echography
Study: NCT03895554

Intervention type: PROCEDURE
Intervention: cardiac PET stress test
Description: Volunteers will undergo cardiac PET stress testing
Study: NCT01132625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Study: NCT03594539

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Withholding standard phosphate binder
Description: In this trial, placebo represents the intervention and not the control. Standard therapy for hyperphosphatemia in end-stage renal disease includes treatment with a phosphate binder. In this trial the intervention will be to withhold the phosphate binder and use placebo instead. In this way the effect of a higher serum phosphate can be evaluated.
Study: NCT03122119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Joint Injection
Description: 30 to 50 milliliters of venous blood will be drawn from the patients arm with a 19 gauge ¾ inch needle using universal precautions. The venous blood will be mixed with 8 milliliters of anticoagulant citrate dextrose solution-A (ACD-A). The anti-coagulated blood will then be centrifuged for 15 minutes at 3200 revolutions per minute in the office centrifuge. This will allow plasma to separate from blood cells. The portion of centrifuged blood deficient in platelets will be extracted and discarded. Once the needle is visualized entering the joint capsule via ultrasound guidance and the physician feels resistance provided by the capsule and ligaments, 3 milliliters of PRP extract will be injected (3 inch, 22 gauge needle) into the sacroiliac joint. The needles will be properly disposed.
Study: NCT01924611

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Technique using cotton rolls
Description: Atraumatic Restorative Technique using cotton rolls.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Technique
Description: Atraumatic Restorative Technique is typically used in Minimally invasive Dentistry.~This restoration technique is made using only hand instruments and is possible to be carried out in children in schools.~This particular time, the isolation of the surgical/tooth area was made using rubber dam as saliva barrier.
Study: NCT02886806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BIS XP, Covidien, Ireland
Description: Closed loop for propofol and remifentanil using BIS XP TM, Covidien, Ireland

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EV-1000 TM, Edwards Lifesciences, Irvine, California, USA
Description: Closed loop for fluid perfusion using EV-1000 TM, Edwards Lifesciences, Irvine, CA, USA
Study: NCT02552290

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper Trapezius Stretch
Description: Sustained stretch of upper trapezius muscle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervicothoracic manipulation
Description: Manipulation to the cervicothoracic spine

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Wait
Study: NCT00958763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing, Single - MIS
Description: The Motivational Interviewing Single Arm is delivered individually to participants in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Group
Description: The Motivational Interviewing Group Arm is delivered to participants in groups in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator and with the group, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Group - UCG
Description: The Usual Care Arm is delivered to participants in three brief time-equivalent health promotion sessions. Each session focuses on health promoting activities such as the importance of diet and exercise, need for physical and mental health assessment and enhanced coping for those afflicted with a history of drug and alcohol addiction. In addition participants receive liver health promotion education. Participants are also provided referrals to alcohol treatment programs in the community and offered the 3 series hepatitis A/B vaccine
Study: NCT01392300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (400 Units)
Description: Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
Study: NCT01493687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5024
Description: CD5024 1% Cream, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azelaic acid 15% Gel
Description: Topical Gel applied twice daily
Study: NCT04368650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMP-2
Description: lyophilized Human Bone Morphogenetic Protein-2 was used as an active drug.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRF
Description: For the preparation of sticky bone, the patient's venous blood is collected and centrifuged at 2400rpm for 2min which leads to two different layers in the vacutainer the upper autologous fibrin glue (AFG) and the lower RBC portion, the upper AFG is mixed with a particulate bone graft (hydroxyapatite). Within 5-10 min fibrin meshwork was formed
Study: NCT01299155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReSTOR +3
Description: Bilateral implantation of an Alcon AcrySof ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1 following cataract extraction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LENTIS MPlus
Description: Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) following cataract extraction.
Study: NCT04280653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NDE L68 StableFit® Punctal Plug
Description: Tear lake evaluation of the planned study eye, prior to insertion of the Punctal Plug and then tear lake evaluation at days 7 and 28 after punctal plug insertion.
Study: NCT01719822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yamax Digi-Walker CW-700
Description: A pedometer with a daily step count target set by a physiotherapist.
Study: NCT03513939

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sernova Cell Pouch
Description: The Sernova Cell Pouch will be implanted against the rectus abdominis. The patient will receive either an 8-plug or 10-plug Cell Pouch configuration depending on Cohort assignment. A minimum of three weeks after Cell Pouch implantation, immunosuppression will be initiated and optimized for another 3 weeks. This will allow for proper vascularization of the Cell Pouch chambers and the patient to be stabilized on immunosuppression prior to islet transplantation. A mass of highly purified islets will be transplanted in the Cell Pouch.~Patients who elect to retain the Cell Pouch after completion of the study will be asked to consent to long term safety follow-up, with data collected beyond the study scheduled visits every 3 months for up to 5 years until the last Cell Pouch explant (and then for a minimum of 3 months thereafter).
Study: NCT04296357

Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination
Study: NCT03379194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antibiotic stewardship program
Description: Routine feedback on antibiotic prescriptions in addition to evidence based guidelines for the management of acute respiratory and urinary tract infection and patient leaflets for using antibiotics wisely
Study: NCT03719924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onivyde
Description: onivyde will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel : 80 mg/m2 IV during 60 minutes at D1, D8 and D15
Study: NCT04296357

Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires

Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires
Study: NCT01347710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurpiridaz F18
Description: Injection of Flurpiridaz F18 for the purposes of PET myocardial profusion imaging (MPI) analysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTechnicium (sestamibi or tetrofosmin)
Description: Injection of 99mTc sestamibi or tetrofosmin for the purposes of SPECT MPI analysis
Study: NCT01798394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
Study: NCT00691808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX6171 High Dose
Description: A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX6171 Low Dose
Description: A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.
Study: NCT02901626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arabin Cervical Pessary
Description: The Arabin cervical pessary is a soft, flexible silicone pessary and fits high around the cervix with no rigid metal framework or inflexible edges that put increase pressure on the vaginal wall. It is available in a variety of sizes however three sizes will be used in this study:~Pessary Size upper diameter, lower diameter~1. Nulliparous 65 mm, 32 mm~2. Multiparous 70 mm, 32 mm~3. Alternative 70 mm, 35 mm
Study: NCT00640185

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-089
Description: Subjects will take up to two 40 mg tablets once daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take up to two 40 mg tablets once daily for 8 weeks.
Study: NCT00832767

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SILS™ port laparoscopic cholecystectomy
Description: This interventional arm will have a single incision laparoscopic cholecystectomy procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four Port Laparoscopic Cholecystectomy
Description: This interventional arm will have a traditional four port laparoscopic cholecystectomy procedure.
Study: NCT00793845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: First HDCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: First HDCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: First HDCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Second HDCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Second HDCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Second HDCT
Study: NCT05461820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole
Description: Methimazole used in this study was produced by Merck, Germany, and its trade name is Thyrozol. The specification of this drug is 10mg/ tablet, and its validity period is 36 months. It was approved by FDA in 2009 and listed in China in 2011.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole
Description: Methimazole used in this study was produced by Merck, Germany, and its trade name is Thyrozol. The specification of this drug is 10mg/ tablet, and its validity period is 36 months. It was approved by FDA in 2009 and listed in China in 2011.
Study: NCT02940574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon (Oxytocin)
Description: Syntocinon nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Physiological water (solution of sodium chloride (NaCl) in water))
Description: Placebo nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray